

MOLECULERA LABS

Few things are worse in life than seeing your child suffer from an illness. But imagine how it would feel if the doctors could not diagnose or, even worse, misdiagnosed your child, giving them unnecessary drugs.

Between two and three million children in the United States suffer from neurological symptoms such as motor tics, obsessive compulsive disorders, autism spectrum disorders and behavior disorders. Children experiencing these symptoms often are treated with neuropsychiatric drugs which impact the nervous system. Unfortunately, some of these children do not suffer from neurological disorders at all; they may be experiencing an autoimmune response to an infection, such as strep throat or Lyme disease, which can be treated with antibiotics, anti-inflammatory drugs and immune modulators. Until recently, there was no test to properly identify children suffering from this condition known as PANDAS.



Using licensed research developed by Dr. Madeline Cunningham at the University of Oklahoma Health Sciences Center, Moleculera Labs now offers a blood test to properly identify PANDAS in children all over the world, enabling their physicians to effectively treat them. With the support of OCAST through the Seed Capital Investment Fund, managed by i2E, Moleculera Labs was able to bring this test to market in 2013. In addition to helping children around the world, the tests will bring jobs and increased tax revenue to Oklahoma through the sale of the tests which is covered by most insurance providers. In the next five years, the company expects to grow from its current 5 employees to 50 employees. A requirement of the Seed Capital Investment Fund is that Oklahoma will receive more than its original investment, sustaining future investments.

[Go to the Moleculera website](#)